Nuochengjianhua announced today that the joint program of obutinib and mesutoclax has been certified as a breakthrough therapy by the Drug Evaluation Center of the State Drug Administration to treat patients with lymphoma in marginal regions who have received at least one treatment in the past. Obutinib is a highly selective, novel BTK inhibitor independently developed by Nuochengjianhua. It can effectively avoid adverse reactions caused by off-target effects and significantly improve efficacy and safety. MesutocLAX is a novel oral highly selective BCL2 inhibitor independently developed by the company. It selectively inhibits BCL2 protein and restores tumor cell apoptosis, thereby inhibiting tumor growth and spread.

Nuochengjianhua announced today that the joint program of obutinib and mesutoclax has been certified as a breakthrough therapy by the Drug Evaluation Center of the State Drug Administration to treat patients with lymphoma in marginal regions who have received at least one treatment in the past. Obutinib is a highly selective, novel BTK inhibitor independently developed by Nuochengjianhua. It can effectively avoid adverse reactions caused by off-target effects and significantly improve efficacy and safety. MesutocLAX is a novel oral highly selective BCL2 inhibitor independently developed by the company. It selectively inhibits BCL2 protein and restores tumor cell apoptosis, thereby inhibiting tumor growth and spread.